WAVE Life Sciences Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--()--WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical company using its proprietary chemistry platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates, today announced the pricing of its initial public offering of 6,375,000 ordinary shares at a price to the public of $16.00 per share. In addition, WAVE Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 956,250 ordinary shares. The ordinary shares are expected to begin trading on The NASDAQ Global Market on November 11, 2015 under the symbol "WVE".

Jefferies and Leerink Partners are acting as joint book-running managers for the offering. JMP Securities and SunTrust Robinson Humphrey are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: [email protected]; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6142, e-mail: [email protected].

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on November 10, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

Feinstein Kean Healthcare
Jessi Colund, 952-649-8600

 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.